Comparing survival and clinical characteristics of patients with non-small cell lung cancer who received immune checkpoint inhibitor therapy less than and more than 2 years

被引：0
|
作者：
Rose, Brandon Edward
Edwards, Kyle
Kareff, Samuel A.
Ramos, Leana
El-Abbar, Nora
Lopes, Gilberto
Rodriguez, Estelamari
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Jackson Mem Hosp, Miami, FL USA
[4] Univ Miami, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21214
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EGFR inhibitors in non-small cell lung cancer: More than yesterday (but less than tomorrow)
    Cortot, A. B.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2010, 66 (06) : 367 - 374
  • [2] Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy
    Mock, J.
    Wynter, E.
    Young, P.
    Sytov, A.
    Elghawy, O.
    Gentzler, R.
    Novicoff, W.
    Martin, L.
    Hall, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S20 - S21
  • [3] Optimal Duration of Immune Checkpoint Inhbitors in Non-small Cell Lung Cancer: Less Is More?
    Blanco Clemente, M.
    Collazo-Lorduy, A.
    Calvo de Juan, V.
    Ospina Serrano, V.
    Sanchez Gonzalez, J. C.
    Nunez Garcia, B.
    Royuela, A.
    Martinez Cutillas, M.
    Garitaonaindia Diaz, Y.
    Traseira Puchol, C.
    Aguado Noya, R.
    Ruiz de Domingo, D.
    Provencio Pulla, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S627 - S628
  • [4] Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
    Conroy, Michael R.
    Dennehy, Colum
    Forde, Patrick M.
    LUNG CANCER, 2023, 183
  • [5] PATIENT EXPERIENCE OF IMMUNE CHECKPOINT INHIBITOR THERAPY FOR NON-SMALL CELL LUNG CANCER
    Williams, Loretta A.
    Whisenant, Meagan
    Malveaux, Donna
    Singhi, Eric K.
    Altan, Mehmet
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [6] Immune Checkpoint Therapy in Non-Small Cell Lung Cancer
    Marrone, Kristen A.
    Brahmer, Julie R.
    CANCER JOURNAL, 2016, 22 (02): : 81 - 91
  • [7] Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy
    Lee, Ji Hyun
    Kang, Danbee
    Ahn, Jin Seok
    Guallar, Eliseo
    Cho, Juhee
    Lee, Ho Yun
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2023, 14 (06) : 2898 - 2907
  • [8] Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review
    Zhang, Hao
    Hu, Yujun
    Wu, Tingting
    Chen, Yeshan
    Yang, Bin
    Xie, Tao
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [9] Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer
    Kang, Da Hyun
    Choi, Chang-Min
    Park, Cheol-Kyu
    Oh, In-Jae
    Kim, Young-Chul
    Yoon, Seong Hoon
    Kim, Yoonjoo
    Lee, Jeong Eun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (04) : 483 - 493
  • [10] METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) WITH MORE THAN 3 YEARS SURVIVAL
    Arancibia, Jorge
    Aren, Osvaldo
    Ascui, Rodrigo
    Cerda, Humberto
    Fernandez, Cristina
    Zambrano, Victor
    Cancino, Daniel
    Carcamo, Marcela
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S117 - S118
12345